Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | BAX | Q07812 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.41 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16506970 | 0.79 | LPAR1 (0.53) | PARP10MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL16506568 | 0.79 | LPAR1 (0.56) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5755276 | 0.77 | P4HTM (0.63) | ALKBH1SRD5A2AKR1C3PARP10P4HTM | |
| Diphenylether SCHEMBL1965337 | 0.75 | LTA4H (0.75) | SRD5A2AKR1C3LTA4HTSHRPARP10 | |
| Diphenylether SCHEMBL360280 | 0.75 | LTA4H (0.75) | SRD5A2AKR1C3LTA4HTSHRPARP10 | |
| Diphenylether SCHEMBL5606885 | 0.75 | LTA4H (0.75) | SRD5A2AKR1C3LTA4HTSHRPARP10 | |
| SCHEMBL19808942 | 0.73 | EGLN1 (0.66) | ALKBH1SRD5A2AKR1C3LTA4HTSHR | |
| SCHEMBL19408509 | 0.72 | LTA4H (0.55) | ALKBH1LTA4HTSHRMEN1KMT2A | |
| SCHEMBL754535 | 0.72 | LTA4H (0.55) | ALKBH1LTA4HTSHRNR1H2BAX | |
| SCHEMBL16344897 | 0.72 | LTA4H (0.55) | ALKBH1LTA4HTSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-1422218-B1 | ANTIVIRAL AGENT | SHIONOGI & CO (JP) | 2012-03-21 | — | — | EP | disclosed |
| CN-101513402-B | Antiviral agent | SHIONOGI & CO | 2012-03-21 | — | — | CN | disclosed |
| CN-101513402-A | Antiviral agent | SHIONOGI & CO (JP) | 2009-08-26 | — | — | CN | disclosed |
| US-7566781-B2 | Imidazopyridine compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| CN-100491349-C | Antiviral agent | SHIONOGI & CO (JP) | 2009-05-27 | — | — | CN | disclosed |
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | BANYU PHARMACEUTICAL., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| CN-1950372-A | imidazopyridine compounds | BANYU PHARMA CO LTD (JP) | 2007-04-18 | — | — | CN | disclosed |
| EP-1748048-A1 | IMIDAZOPYRIDINE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-31 | — | — | EP | disclosed |
| CN-1558898-A | Antiviral agent | ��Ұ����ҩ��ʽ���� | 2004-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | MC1R, MCHR2, MCHR1 | ALKBH1 1514/4885SRD5A2 249/4885AKR1C3 291/4885 |
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | ALKBH1 143/4885SRD5A2 239/4885AKR1C3 577/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | ALKBH1 143/4885SRD5A2 239/4885AKR1C3 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.